(Q33418595)

English

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

13

object named as

D Ross Camidge

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Robert C Doebele

1

object named as

Robert C Doebele

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

David Spigel

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mustapha Tehfe

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sachdev Thomas

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Martin Reck

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sunil Verma

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Janice Eakle

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Frederique Bustin

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jerome Goldschmidt

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dachuang Cao

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ekaterine Alexandris

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sergey Yurasov

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Philip Bonomi

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

6 November 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

121

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

883-892

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

Angiogenesis in cancer, vascular, rheumatoid and other disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

Tumor angiogenesis: past, present and the near future

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

Angiogenesis in cancer and other diseases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

Markers of response for the antiangiogenic agent bevacizumab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

21 January 2018

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

7 January 2021

based on heuristic

inferred from DOI database lookup

Vascular endothelial growth factor and its receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29132

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.29132

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33418595&oldid=1971561009"